[1] CLEGG A, YOUNG J, ILIFFE S, et al.Frailty in elderly people[J]. Lancet(London, England),2013,381(9868):752-762. [2] CHEN X, MAO G, LENG S X.Frailty syndrome: an overview[J]. Clin Interv Aging,2014,9:433-441. [3] EVANS N R, TODD O M, MINHAS J S, et al.Frailty and cerebrovascular disease: Concepts and clinical implications for stroke medicine[J]. Int J Stroke,2022,17(3):251-259. [4] KILKENNY M F, PHAN H T, LINDLEY R I, et al.Utility of the Hospital Frailty Risk Score Derived From Administrative Data and the Association With Stroke Outcomes[J]. Stroke,2021,52(9):2874-2881. [5] PALMER K, VETRANO D L, PADUA L, et al.Frailty Syndromes in Persons With Cerebrovascular Disease: A Systematic Review and Meta-Analysis[J]. Front Neurol,2019,10:1255-1262. [6] LAWLOR D A, HARBORD R M, STERNE J A C, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology[J]. Stat Med,2008,27(8):1133-1163. [7] ATKINS J L, JYLHÄVÄ J, PEDERSEN N L, et al. A genome-wide association study of the frailty index highlights brain pathways in ageing[J]. Aging Cell,2021,20(9):e13459. [8] DAVEY SMITH G, HOLMES M V, DAVIES N M, et al.Mendel’s laws, Mendelian randomization and causal inference in observational data: substantive and nomenclatural issues[J]. Eur J Epidemiol,2020,35(2):99-111. [9] SWERDLOW D I, KUCHENBAECKER K B, SHAH S, et al.Selecting instruments for Mendelian randomization in the wake of genome-wide association studies[J]. Int J Epidemiol,2016,45(5):1600-1616. [10] DAVEY SMITH G, HEMANI G.Mendelian randomization: genetic anchors for causal inference in epidemiological studies[J]. Hum Mol Genet,2014,23(R1):R89-98. [11] HEMANI G, ZHENG J, ELSWORTH B, et al.The MR-Base platform supports systematic causal inference across the human phenome[J]. eLife,2018,7:e34408. [12] CHEN L, YANG H, LI H, et al.Insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study[J]. Hepatology,2022,75(4):785-796. [13] SANDERSON E, SPILLER W, BOWDEN J.Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomization[J]. Stat Med,2021,40(25):5434-5452. [14] MALIK R, CHAUHAN G, TRAYLOR M, et al.Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes[J]. Nat Genet,2018,50(4):524-537. [15] BURGESS S, BUTTERWORTH A, THOMPSON S G.Mendelian randomization analysis with multiple genetic variants using summarized data[J]. Genet Epidemiol,2013,37(7):658-665. [16] BURGESS S, THOMPSON S G.Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects[J]. Am J Epidemiol,2015,181(4):251-260. [17] BURGESS S, BOWDEN J, FALL T, et al.Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants[J]. Epidemiology,2017,28(1):30-42. [18] BOWDEN J, DEL GRECO M F, MINELLI C, et al. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization[J]. Stat Med,2017,36(11):1783-1802. [19] BOWDEN J, DAVEY SMITH G, BURGESS S.Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression[J]. Int J Epidemiol,2015,44(2):512-525. [20] BOWDEN J, SPILLER W, DEL GRECO M F, et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression[J]. Int J Epidemiol,2018,47(4):1264-1278. [21] HEMANI G, BOWDEN J, DAVEY SMITH G.Evaluating the potential role of pleiotropy in Mendelian randomization studies[J]. Hum Mol Genet,2018,27(R2):R195-R208. [22] BURGESS S, THOMPSON S G.Interpreting findings from Mendelian randomization using the MR-Egger method[J]. Eur J Epidemiol,2017,32(5):377-389. [23] LOCKE A E, KAHALI B, BERNDT S I, et al.Genetic studies of body mass index yield new insights for obesity biology[J]. Nature,2015,518(7538):197-206. [24] DÖNERTAŞ H M, FABIAN D K, VALENZUELA M F, et al. Common genetic associations between age-related diseases[J]. Nat Aging, 2021,1(4):400-412. [25] LIGTHART S, VAEZ A, VÕSA U, et al. Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders[J]. Am J Hum Genet,2018,103(5):691-706. [26] OFORI-ASENSO R, CHIN K L, MAZIDI M, et al.Global Incidence of Frailty and Prefrailty Among Community-Dwelling Older Adults: A Systematic Review and Meta-analysis[J]. JAMA netw open,2019,2(8):e198398. [27] MITNITSKI A B, MOGILNER A J, ROCKWOOD K.Accumulation of deficits as a proxy measure of aging[J]. The Scientific World Journal,2001,1:323-336. [28] HOOGENDIJK E O, AFILALO J, ENSRUD K E, et al.Frailty: implications for clinical practice and public health[J]. Lancet,2019,394(10206):1365-1375. [29] DENT E, KOWAL P, HOOGENDIJK E O.Frailty measurement in research and clinical practice: A review[J]. Eur J Intern Med,2016,31:3-10. [30] DOU M, CEN Y, ZHONG J, et al.Association between frailty index based on routine laboratory tests and risk of cerebral small vessel disease in elderly patients: a hospital-based observational study[J]. Aging Cli Exp Res,2022,34(11):2683-2692. [31] Del Brutto O H, Mera R M, Recalde B Y, et al. Mediation of age in the association between frailty and large artery atherosclerosis burden - A population study in community-dwelling older adults[J]. J Stroke Cerebrovasc Dis,2020,29(7):104-112. [32] KANAI M, NOGUCHI M, KUBO H, et al.Pre-Stroke Frailty and Stroke Severity in Elderly Patients with Acute Stroke[J]. J Stroke Cerebrovasc Dis,2020,29(12):105-111 [33] NEWMAN A B, GOTTDIENER J S, MCBURNIE M A, et al.Associations of subclinical cardiovascular disease with frailty[J]. J Gerontol A Biol Sci Med Sci,2001,56(3):158-166. [34] DAMLUJI A A, CHUNG S E, XUE Q L, et al.Frailty and cardiovascular outcomes in the National Health and Aging Trends Study[J]. Eur Heart J,2021,42(37):3856-3865. [35] WALSTON J, MCBURNIE M A, NEWMAN A, et al.Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study[J]. Arch Intern Med,2002,162(20):2333-2341. [36] RIDKER P M, LIBBY P, MACFADYEN J G, et al.Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)[J]. Eur Heart J,2018,39(38):3499-3507. [37] KOCHAR B, ORKABY A R, ANANTHAKRISHNAN A N, et al.Frailty in inflammatory bowel diseases: an emerging concept[J]. Therap Adv Gastroenterol,2021,14:175-184. [38] BIGEH A, SANCHEZ A, MAESTAS C, et al.Inflammatory bowel disease and the risk for cardiovascular disease: Does all inflammation lead to heart disease?[J]. Trends Cardiovasc Med,2020,30(8):463-469. [39] KAMPERIDIS N, KAMPERIDIS V, ZEGKOS T, et al.Atherosclerosis and Inflammatory Bowel Disease-Shared Pathogenesis and Implications for Treatment[J]. Angiology,2021,72(4):303-314. |